» Articles » PMID: 11286467

Chromosomal Radiosensitivity As a Marker of Predisposition to Common Cancers?

Overview
Journal Br J Cancer
Specialty Oncology
Date 2001 Apr 5
PMID 11286467
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

We previously found that 40% of breast cancer patients showed enhanced sensitivity to X-ray induced chromosome damage in G(2)lymphocytes and suggested that this might indicate a low penetrance predisposition to breast cancer, for which there is good epidemiological evidence. We have now tested the hypothesis that elevated G(2)radiosensitivity is a marker of such predisposition to other common cancers. We tested patients with colorectal cancer, for which there is also good epidemiological evidence of inherited risk in a substantial proportion of cases, and patients with cancers having a strong environmental aetiology (lung and cervix). We also repeated our study of breast cancer cases and tested patients with chronic diseases other than cancer. The results support our hypothesis, in that 30% (12/37) of colorectal cases showed enhanced sensitivity compared with 9% (6/66) of normal healthy controls (P = 0.01), whereas the proportions of sensitive cervix (11%, 3/27, P = 0.72) and lung cancer cases (23%, 8/35, P = 0.07) were not significantly above normals. We confirmed the enhanced sensitivity of 40% (12/31, P = 0.001) of breast cancer patients and found that patients with non-malignant disease had a normal response in the assay (12%, 4/34, P = 0.73). We suggest that enhanced G(2)chromosomal radiosensitivity is a consequence of inherited defects in the ability of cells to process DNA damage from endogenous or exogenous sources, of a type that is mimicked by ionizing radiation, and that such defects predispose to breast and colorectal cancer.

Citing Articles

Radiation symptoms resemble laminopathies and the physical underlying cause may sit at the lamin A C-terminus.

Waldherr A, Fogtman A Mol Med. 2025; 31(1):69.

PMID: 39979866 PMC: 11844092. DOI: 10.1186/s10020-025-01081-0.


Organ-on-a-chip: the next generation platform for risk assessment of radiobiology.

Quan Y, Sun M, Tan Z, Eijkel J, van den Berg A, van der Meer A RSC Adv. 2022; 10(65):39521-39530.

PMID: 35515392 PMC: 9057494. DOI: 10.1039/d0ra05173j.


Telomere Length Dynamics and Chromosomal Instability for Predicting Individual Radiosensitivity and Risk via Machine Learning.

Luxton J, McKenna M, Lewis A, Taylor L, Jhavar S, Swanson G J Pers Med. 2021; 11(3).

PMID: 33800260 PMC: 8002073. DOI: 10.3390/jpm11030188.


Spontaneous and Radiation-Induced Chromosome Aberrations in Primary Fibroblasts of Patients With Pediatric First and Second Neoplasms.

Zahnreich S, Poplawski A, Hartel C, Eckhard L, Galetzka D, Hankeln T Front Oncol. 2020; 10:1338.

PMID: 32850427 PMC: 7427586. DOI: 10.3389/fonc.2020.01338.


Comparing Lymphocyte Radiosensitivity of Prostate Cancer Patients with Healthy Donors Using Micronuclei and Chemical Premature Chromosome Condensation Tests.

F G, B H, A H, A N J Biomed Phys Eng. 2020; 10(4):411-420.

PMID: 32802789 PMC: 7416091. DOI: 10.31661/JBPE.V0I0.657.


References
1.
Levi F . Cancer prevention: epidemiology and perspectives. Eur J Cancer. 1999; 35(7):1046-58. DOI: 10.1016/s0959-8049(99)00094-5. View

2.
Roberts S, Spreadborough A, Bulman B, Barber J, Evans D, Scott D . Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?. Am J Hum Genet. 1999; 65(3):784-94. PMC: 1377987. DOI: 10.1086/302544. View

3.
Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

4.
Peto J, Mack T . High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000; 26(4):411-4. DOI: 10.1038/82533. View

5.
Han T, Takita H . Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin. Cancer. 1972; 30(3):616-20. DOI: 10.1002/1097-0142(197209)30:3<616::aid-cncr2820300304>3.0.co;2-q. View